Combined anti-prolactin and anti-oestrogen therapy for breast carcinoma.
D000368:Aged; D001943:Breast Neoplasms / Q000188:drug therapy*; D001971:Bromocriptine / Q000009:adverse effects / Q000627:therapeutic use; D002230:Carbidopa / Q000009:adverse effects / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004965:Estrogen Antagonists; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D011388:Prolactin / Q000037:antagonists & inhibitors*; D012075:Remission, Spontaneous; D013267:Stilbenes / Q000627:therapeutic use*; D013629:Tamoxifen / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014839:Vomiting / Q000139:chemically induced
D004965:Estrogen Antagonists; D013267:Stilbenes; D013629:Tamoxifen; D001971:Bromocriptine; D007980:Levodopa; D011388:Prolactin; D002230:Carbidopa